Iopromide

Iopromide

Iopromide

Chemical compound

Iopromide is an iodinated contrast medium for X-ray imaging. It is marketed under the name Ultravist which is produced by Bayer Healthcare. It is a low osmolar, non-ionic contrast agent for intravascular use; i.e., it is injected into blood vessels.[2]

Quick Facts Clinical data, Trade names ...

It is commonly used in radiographic studies such as intravenous urograms, brain computer tomography (CT)[2] and CT pulmonary angiograms (CTPAs).

Medical uses

The radiocontrast agent is given intravenously in computed tomography (CT) scans, angiography and excretory urography.[3]

Contraindications

Iopromide use is contraindicated in myelography, cerebral ventriculography and cisternography procedures. It is also contraindicated in those with hyperthyroidism, or with known allergy to the drug.[4]

Iopromide is also contraindicated in children with prolonged fasting, fluid restriction, on laxative, or dehydration as it can cause renal failure.[4]

References

  1. [1]
    "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. [2]
    Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Ultravist 300 mg J/ml-Infusionsflaschen.
  3. [3]
    "Prescribing information - Ultravist" (PDF). Bayer Healthcare pharmaceuticals. Archived from the original (PDF) on 10 April 2021.
  4. [4]
    "PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ULTRAVIST® Iopromide Injection" (PDF). Bayer Healthcare Pharmaceuticals. Archived from the original (PDF) on 27 October 2021. Retrieved 16 April 2024.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Iopromide, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.